These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24156566)

  • 21. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H; Mailänder C; Baier M; Kirsten A
    BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
    Costa-Scharplatz M; Ställberg B; Goyal P; Asukai Y; Gruenberger JB; Price D
    Appl Health Econ Health Policy; 2015 Dec; 13(6):637-45. PubMed ID: 26324401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
    Rodrigo GJ; Plaza V
    Chest; 2014 Aug; 146(2):309-317. PubMed ID: 24556877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
    Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
    Wedzicha JA; Dahl R; Buhl R; Schubert-Tennigkeit A; Chen H; D'Andrea P; Fogel R; Banerji D
    Respir Med; 2014 Oct; 108(10):1498-507. PubMed ID: 25135743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
    Rogliani P; Calzetta L; Ora J; Lipsi R; Segreti A; Matera MG; Cazzola M
    Eur J Pharmacol; 2015 Aug; 761():383-90. PubMed ID: 25952728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
    Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
    Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
    Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
    Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
    Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
    Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study.
    Kerwin E; Siler TM; Korenblat P; White A; Eckert JH; Henley M; Patalano F; D'Andrea P
    Chronic Obstr Pulm Dis; 2016 Mar; 3(2):549-559. PubMed ID: 28848879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
    Santus P; Radovanovic D; Di Marco F; Raccanelli R; Valenti V; Centanni S
    Pulm Pharmacol Ther; 2015 Dec; 35():42-9. PubMed ID: 26549785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
    Kerwin E; Ferguson GT; Sanjar S; Goodin T; Yadao A; Fogel R; Maitra S; Sen B; Ayers T; Banerji D
    Lung; 2017 Dec; 195(6):739-747. PubMed ID: 28993871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
    Ulrik CS
    Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.